靶向血液系统恶性肿瘤中的 microRNA。
Targeting microRNA in hematologic malignancies.
机构信息
Division of Dermatology.
Beckman Research Institute, City of Hope, Duarte, California, USA.
出版信息
Curr Opin Oncol. 2020 Sep;32(5):535-544. doi: 10.1097/CCO.0000000000000657.
Abstract
PURPOSE OF REVIEW
MiRNAs are critical regulators for gene expression. Numerous studies have revealed how miRNAs contribute to the pathogenesis of hematologic malignancies.
RECENT FINDINGS
The identification of novel miRNA regulatory factors and pathways crucial for miRNA dysregulation has been linked to hematologic malignancies. miRNA expression profiling has shown their potential to predict outcomes and treatment responses. Recently, targeting miRNA biogenesis or pathways has become a promising therapeutic strategy with recent miRNA-therapeutics being developed.
SUMMARY
We provide a comprehensive overview of the role of miRNAs for diagnosis, prognosis, and therapeutic potential in hematologic malignancies.
摘要
目的综述
miRNAs 是基因表达的关键调节因子。大量研究揭示了 miRNAs 如何导致血液系统恶性肿瘤的发病机制。
最近的发现
鉴定新的 miRNA 调控因子和途径对于 miRNA 失调至关重要，与血液系统恶性肿瘤有关。miRNA 表达谱分析表明其具有预测结局和治疗反应的潜力。最近，靶向 miRNA 生物发生或途径已成为一种有前途的治疗策略，最近正在开发 miRNA 治疗药物。
总结
我们全面概述了 miRNAs 在血液系统恶性肿瘤中的诊断、预后和治疗潜力。
相似文献
1
Targeting microRNA in hematologic malignancies.靶向血液系统恶性肿瘤中的 microRNA。
Curr Opin Oncol. 2020 Sep;32(5):535-544. doi: 10.1097/CCO.0000000000000657.
2
Role of microRNAs in hematological malignancies.miRNAs 在血液系统恶性肿瘤中的作用。
Expert Rev Hematol. 2009 Aug;2(4):415-23. doi: 10.1586/ehm.09.32.
3
MicroRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies.微小 RNA 多态性作为血液系统恶性肿瘤风险、预后和治疗反应的标志物。
Crit Rev Oncol Hematol. 2015 Jan;93(1):1-17. doi: 10.1016/j.critrevonc.2014.08.006. Epub 2014 Sep 2.
4
MicroRNA expression and function in cancer.微小RNA在癌症中的表达与功能
Trends Mol Med. 2006 Dec;12(12):580-7. doi: 10.1016/j.molmed.2006.10.006. Epub 2006 Oct 30.
5
MicroRNAs in hematological malignancies.血液恶性肿瘤中的 microRNAs。
Blood Rev. 2013 May;27(3):143-54. doi: 10.1016/j.blre.2013.04.002. Epub 2013 Apr 25.
6
Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies.肿瘤抑制 microRNAs 的甲基化：来自淋巴恶性肿瘤的教训。
Expert Rev Mol Diagn. 2012 Sep;12(7):755-65. doi: 10.1586/erm.12.64.
7
Steroid receptor and microRNA regulation in cancer.甾体激素受体和微小 RNA 在癌症中的调控作用。
Curr Opin Oncol. 2010 Nov;22(6):592-7. doi: 10.1097/CCO.0b013e32833ea80c.
8
The role of microRNAs in the pathogenesis and treatment of hematopoietic malignancies.微小 RNA 在造血系统恶性肿瘤发病机制和治疗中的作用。
Curr Pharm Des. 2013;19(7):1201-10. doi: 10.2174/138161213804805649.
9
Emerging role of let-7 family in the pathogenesis of hematological malignancies.Let-7 家族在血液系统恶性肿瘤发病机制中的新作用。
Biomed Pharmacother. 2021 Dec;144:112334. doi: 10.1016/j.biopha.2021.112334. Epub 2021 Oct 13.
10
MicroRNAs in hematological malignancies: a novel approach to targeted therapy.血液系统恶性肿瘤中的微小RNA：靶向治疗的新方法。
Hematology. 2012 May;17(3):170-5. doi: 10.1179/102453312X13376952196656.
引用本文的文献
1
MicroRNA Signatures: Illuminating Minimal Residual Disease Monitoring in Juvenile Myelomonocytic Leukemia - A Review.微小RNA特征：照亮青少年骨髓单核细胞白血病微小残留病监测——综述
J Hematol. 2025 Apr;14(2):43-55. doi: 10.14740/jh1384. Epub 2025 Apr 25.
2
The Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies: A Central Study.阿托伐他汀对血液系统恶性肿瘤中致癌性微小RNA的影响：一项核心研究。
Biomolecules. 2024 Dec 7;14(12):1559. doi: 10.3390/biom14121559.
3
Clinical implications of miRNAs in erythropoiesis, anemia, and other hematological disorders.miRNAs 在红细胞生成、贫血和其他血液系统疾病中的临床意义。
Mol Biol Rep. 2024 Oct 18;51(1):1064. doi: 10.1007/s11033-024-09981-w.
4
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia.miR-15a 靶向慢性髓性白血病中的 HSP90 共伴侣 Morgana。
Sci Rep. 2024 Jul 2;14(1):15089. doi: 10.1038/s41598-024-65404-7.
5
Dysregulation of Non-Coding RNAs: Roles of miRNAs and lncRNAs in the Pathogenesis of Multiple Myeloma.非编码RNA的失调：微小RNA和长链非编码RNA在多发性骨髓瘤发病机制中的作用
Noncoding RNA. 2023 Nov 3;9(6):68. doi: 10.3390/ncrna9060068.
6
Clinical Significance of microRNAs in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation.微小RNA在血液系统恶性肿瘤和造血干细胞移植中的临床意义
Cancers (Basel). 2023 May 8;15(9):2658. doi: 10.3390/cancers15092658.
7
Advances in the application of Raman spectroscopy in haematological tumours.拉曼光谱在血液系统肿瘤中的应用进展
Front Bioeng Biotechnol. 2023 Jan 10;10:1103785. doi: 10.3389/fbioe.2022.1103785. eCollection 2022.
8
Role of microRNAs in B-Cell Compartment: Development, Proliferation and Hematological Diseases.微小RNA在B细胞区室中的作用：发育、增殖及血液系统疾病
Biomedicines. 2022 Aug 18;10(8):2004. doi: 10.3390/biomedicines10082004.
9
Identification of uPAR Variants Acting as ceRNAs in Leukaemia Cells.白血病细胞中作为竞争性内源RNA发挥作用的尿激酶型纤溶酶原激活物受体（uPAR）变体的鉴定
Cancers (Basel). 2022 Apr 14;14(8):1980. doi: 10.3390/cancers14081980.
10
One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.一种组学方法并不能解决所有问题：代谢组学与表观基因组学在血液系统恶性肿瘤中携手合作。
Epigenomes. 2021 Oct 8;5(4):22. doi: 10.3390/epigenomes5040022.
本文引用的文献
1
MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.MN1、FOXP1和hsa-miR-181a-5p作为接受强化诱导化疗和自体干细胞移植的急性髓系白血病患者的预后标志物。
Leuk Res. 2020 Feb;89:106296. doi: 10.1016/j.leukres.2020.106296. Epub 2020 Jan 3.
2
The emerging role of microRNAs in the molecular diagnosis of mycosis fungoides.微小RNA在蕈样肉芽肿分子诊断中的新兴作用。
Br J Dermatol. 2019 May;180(5):984-985. doi: 10.1111/bjd.17768.
3
Differential expression of miRNAs in acute myeloid leukemia quantified by Nextgen sequencing of whole blood samples.通过对全血样本的下一代测序对急性髓细胞白血病进行差异表达的 miRNA 定量分析。
PLoS One. 2019 Mar 20;14(3):e0213078. doi: 10.1371/journal.pone.0213078. eCollection 2019.
4
Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.靶向 microRNA-214 治疗皮肤 T 细胞淋巴瘤的临床前研究
J Invest Dermatol. 2019 Sep;139(9):1966-1974.e3. doi: 10.1016/j.jid.2019.01.033. Epub 2019 Mar 12.
5
Publisher Correction: Regulation of microRNA biogenesis and its crosstalk with other cellular pathways.出版商更正：微小RNA生物合成的调控及其与其他细胞途径的相互作用。
Nat Rev Mol Cell Biol. 2019 May;20(5):321. doi: 10.1038/s41580-019-0106-6.
6
Abnormal microRNA expression in the course of hematological malignancies.血液系统恶性肿瘤病程中的微小RNA表达异常。
Cancer Manag Res. 2018 Oct 8;10:4267-4277. doi: 10.2147/CMAR.S174476. eCollection 2018.
7
Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma.考博马林，一种 miR-155 的寡核苷酸抑制剂，协调调节多种存活途径，减少皮肤 T 细胞淋巴瘤中的细胞增殖和存活。
Br J Haematol. 2018 Nov;183(3):428-444. doi: 10.1111/bjh.15547. Epub 2018 Aug 20.
8
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation.微小RNA生物合成、作用机制及循环概述
Front Endocrinol (Lausanne). 2018 Aug 3;9:402. doi: 10.3389/fendo.2018.00402. eCollection 2018.
9
miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFβ signaling.miR-143/145 通过抑制经典 TGFβ 信号通路差异调节造血干细胞和祖细胞的活性。
Nat Commun. 2018 Jun 20;9(1):2418. doi: 10.1038/s41467-018-04831-3.
10
The impact of Mir-9 regulation in normal and malignant hematopoiesis.Mir-9调控在正常和恶性造血过程中的影响。
Oncol Rev. 2018 Mar 27;12(1):348. doi: 10.4081/oncol.2018.348. eCollection 2018 Jan 30.
Zotero 插件